This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Buy These 5 Low-Beta Stocks to Counter Market Volatility
by Nilanjan Banerjee
A low-risk portfolio can garner healthy returns when some specific parameters are considered.
Top Stock Reports for SAP, AbbVie & Sinopec
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including SAP SE (SAP), AbbVie (ABBV) and Sinopec (SNP).
Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs
by Kinjel Shah
Lilly (LLY) issues upbeat financial guidance for 2020. FDA approves label expansion of Pfizer's (PFE) Xtandi and Merck's (MRK) Ebola vaccine, Ervebo.
Gilead (GILD) Files NDA With FDA for RA Candidate Filgotinib
by Zacks Equity Research
Gilead (GILD) files an NDA for filgotinib with the FDA for the treatment of adults with moderate-to-severe rheumatoid arthritis.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Eli Lilly, PNC Financial, EOG Resources and Archer-Daniels-Midland
Pfizer's Braftovi sNDA Accepted by FDA for Priority Review
by Zacks Equity Research
FDA grants priority review to Pfizer's (PFE) sNDA seeking approval of Braftovi in combination with Erbitux as a treatment for advanced colorectal cancer.
Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU
by Zacks Equity Research
The European Commission confers an orphan drug status on Dicerna's (DRNA) RNAi therapeutic DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency.
Lilly's Stock Up on Upbeat Sales & Profit Outlook for 2020
by Zacks Equity Research
Eli Lilly's (LLY) stock up on Tuesday after it provides an upbeat financial guidance for the next year.
Top Stock Reports for Johnson & Johnson, Eli Lilly & PNC Financial
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Eli Lilly (LLY) and PNC Financial (PNC).
Lilly's Cyramza Gets CHMP Recommendation for First-Line NSCLC
by Zacks Equity Research
Lilly's (LLY) regulatory application seeking approval for cancer drug, Cyramza, in combination with erlotinib for treating EGFR-mutated NSCLC in first-line setting gets positive CHMP opinion for approval in EU.
Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study
by Kinjel Shah
This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion
The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Lilly, Charter, Alibaba and Charles Schwab
Top Research Reports for Merck, Eli Lilly & Charter Communications
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Eli Lilly (LLY) and Charter Communications (CHTR).
Lilly (LLY) Up 6.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Lilly (LLY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes Submits NDA to FDA for Schizophrenia & Bipolar I Drug
by Zacks Equity Research
Alkermes (ALKS) submits NDA to the FDA seeking approval of ALKS 3831 for the treatment of schizophrenia and bipolar I disorder.
Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates
by Kinjel Shah
Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
by Zacks Equity Research
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.
4 Biotech Stocks That Could Keep Beating Wall Street
by Zacks Equity Research
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Aduro (ADRO) Q3 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Aduro's (ADRO) loss misses estimates in Q3 while revenues almost match the mark.
Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales
by Zacks Equity Research
Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.
Nektar (NKTR) Q3 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.
Allergan (AGN) Meets Q3 Earnings Estimates, Ups '19 Sales View
by Zacks Equity Research
Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Value Biotech ETFs & Stocks to Buy Now
by Sanghamitra Saha
Biotech valuation looks attractive amid a volley of good news. Investors can tap these stocks and ETFs.
What's in the Cards for Teva (TEVA) This Earnings Season?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q3 sales